Phase 1 study of quadrivalent flu vaccine (mRNA-1010) successfully boosted titers against all four strains in older and younger adults, even at lowest dose; no significant safety concerns were observed
The proposed week-long event will comprise specific themes - International engagements, market access and incubation support, funding support to startups etc. and will cover the different areas of the innovation lifecycle
It is a novel oral NLRP3 inflammasome inhibitor
Over the next few years, Philips aims to double the number of its active cath labs in India with a special focus on improving accessibility to quality cardiac and neurovascular care in tier 2 and tier 3 cities
The company will donate 5000 nebulizers to primary health care centres in rural India
Brii Bio announces amubarvimab/romlusevimab combination received approval from NMPA
The interim results of Phase 3 clinical trials conducted by CanSinoBIO demonstrated that Convidecia has an efficacy of 95.47% at preventing severe disease 14 days after single-dose vaccination.
The tablets are indicated for the treatment of pulmonary arterial hypertension
According to the companies’ preliminary data, a third dose provides a similar level of neutralizing antibodies to Omicron as is observed after two doses against wild-type and other variants that emerged before Omicron
An MoU was signed between B Medical Systems and Gujarat government recently
Subscribe To Our Newsletter & Stay Updated
